As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

CHICA­GO — Adding As­traZeneca’s Imfinzi and Lyn­parza to the treat­ment reg­i­men for pa­tients with ad­vanced ovar­i­an can­cer and no BR­CA mu­ta­tion ex­tend­ed pro­gres­sion-free sur­vival (PFS) by five months, ac­cord­ing to in­ter­im da­ta re­leased at the AS­CO an­nu­al meet­ing Sat­ur­day morn­ing.

How­ev­er, the de­sign of the Phase III study ob­scures how much Imfinzi is con­tribut­ing to the PFS ex­ten­sion, doc­tors said, mak­ing it dif­fi­cult to ap­ply the find­ings to clin­i­cal prac­tice.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.